| Recruiting | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) NCT06661915 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Efficacy and Safety of Peginterferon in ET and PV. NCT06734637 | Zhenya Hong | N/A |
| Recruiting | Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET NCT06552429 | Xiamen Amoytop Biotech Co., Ltd. | Phase 2 |
| Recruiting | Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) NCT06456346 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes NCT06361641 | University Hospital, Angers | N/A |
| Recruiting | A Study of GLB-001 in Patients With Myeloid Malignancies NCT06378437 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, NCT06063486 | University of Southern California | Phase 2 |
| Recruiting | A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essent NCT06079879 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Asian Myeloproliferative Neoplasm (MPN) Registry NCT05882773 | The University of Hong Kong | — |
| Recruiting | Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm NCT05025488 | Marina Kremyanskaya | Phase 1 |
| Active Not Recruiting | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET NCT05482971 | PharmaEssentia | Phase 2 |
| Recruiting | AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V61 NCT05198960 | University Hospital, Brest | Phase 3 |
| Recruiting | Ruxolitinib in Thrombocythemia and Polycythemia Vera NCT04644211 | Massachusetts General Hospital | Phase 2 |
| Recruiting | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms NCT05123365 | University of California, Irvine | Phase 1 / Phase 2 |
| Recruiting | Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syn NCT04942080 | University Hospital, Angers | N/A |
| Recruiting | Two Step Haplo With Radiation Conditioning NCT05031897 | Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) NCT04262141 | Terrence J Bradley, MD | Phase 2 |
| Completed | Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) NCT04254978 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Phase 2 |
| Active Not Recruiting | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistan NCT04285086 | PharmaEssentia | Phase 3 |
| Recruiting | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloprolif NCT04282187 | University of Washington | Phase 2 |
| Completed | Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. NCT03869476 | University Hospital, Angers | N/A |
| Completed | Dual Vaccine Trial in Myeloproliferative Neoplasms NCT04051307 | Inge Marie Svane | Phase 1 / Phase 2 |
| Terminated | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia NCT03972943 | University of Utah | EARLY_Phase 1 |
| Active Not Recruiting | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT03862157 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myelop NCT03878199 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase NCT03907436 | University of California, Irvine | N/A |
| Active Not Recruiting | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Diso NCT03289910 | National Cancer Institute (NCI) | Phase 2 |
| Completed | CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms NCT03566446 | Inge Marie Svane | Phase 1 |
| Completed | Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) NCT03745378 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | — |
| Terminated | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms NCT03121599 | Hamad Medical Corporation | N/A |
| Completed | Anagre Cap. in Patients With High-Risk Essential Thrombocythemia NCT03232177 | Yuhan Corporation | Phase 4 |
| Unknown | 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia NCT03116542 | Hamad Medical Corporation | N/A |
| Completed | Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms NCT02823184 | University Hospital, Bordeaux | — |
| Completed | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms NCT06371573 | Federico II University | — |
| Terminated | The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line NCT02962388 | French Innovative Leukemia Organisation | Phase 2 / Phase 3 |
| Withdrawn | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders NCT02663648 | Shandong University | — |
| Unknown | Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia NCT02611973 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malig NCT02556931 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | Myeloproliferative Neoplastic Diseases Observatory From Brest NCT02897297 | University Hospital, Brest | — |
| Recruiting | Myeloproliferative Neoplasms (MPNs) Patient Registry NCT02760238 | University Health Network, Toronto | — |
| Completed | Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia NCT02407080 | John Mascarenhas | Phase 1 |
| Completed | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation NCT02311569 | Swiss Cancer Institute | Phase 2 |
| Completed | Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients NCT02893410 | University Hospital, Brest | — |
| Completed | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies NCT02129101 | Mayo Clinic | Phase 1 |
| Completed | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera My NCT02124746 | Sierra Oncology LLC - a GSK company | Phase 2 |
| Terminated | Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia NCT01998828 | Sierra Oncology LLC - a GSK company | Phase 2 |
| Completed | Anagrelide Retard in Essential Thrombocythemia NCT02076815 | AOP Orphan Pharmaceuticals AG | Phase 3 |
| Completed | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF NCT01787552 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Myeloproliferative Neoplasms: an In-depth Case-control Study NCT01831635 | Queen's University, Belfast | — |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients NCT01970930 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms NCT01520220 | Eli Lilly and Company | Phase 1 |
| Completed | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms NCT01387763 | Thomas Stauffer Larsen | Phase 3 |
| Completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycyth NCT01243073 | Geron Corporation | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia NCT01192347 | Shire | — |
| Terminated | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis NCT01014546 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia NCT00866762 | Copenhagen University Hospital at Herlev | Phase 2 |
| Completed | Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia NCT00718159 | Eli Lilly and Company | Phase 1 |
| Completed | A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis NCT00745550 | S*BIO | Phase 1 / Phase 2 |
| Unknown | CEP-701 (Lestaurtinib) in Myelofibrosis NCT00668421 | Ronald Hoffman | Phase 1 / Phase 2 |
| Completed | Familial Myeloproliferative Disorders NCT00666289 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leu NCT00588991 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Research Tissue Bank NCT00666549 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Correlative Biomarker Study in Patients With Myeloproliferative Disorders NCT00665067 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, NCT00445744 | Fred Hutchinson Cancer Center | N/A |
| Completed | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, NCT00381550 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes NCT00715247 | University of Utah | — |
| Completed | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treati NCT00397813 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Lenalidomide and Prednisone in Treating Patients With Myelofibrosis NCT00227591 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leuke NCT00052520 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia NCT00047190 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Myelofibrosis NCT00039416 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |